Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T87119
(Former ID: TTDS00463)
|
|||||
| Target Name |
Fungal Cell membrane (Fung CM)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Candidosis [ICD-11: 1F23] | |||||
| 2 | Conjunctiva disorder [ICD-11: 9A60] | |||||
| 3 | Dermatophytosis [ICD-11: 1F28] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
| 1 | Haloprogin | Drug Info | Approved | Dermatophytosis | [2], [3] | |
| 2 | Natamycin | Drug Info | Approved | Conjunctivitis | [2], [4] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Binder | [+] 2 Binder drugs | + | ||||
| 1 | Haloprogin | Drug Info | [5] | |||
| 2 | Natamycin | Drug Info | [1] | |||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | Drug information of Haloprogin, 2008. eduDrugs. | |||||
| REF 4 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050514. | |||||
| REF 5 | Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.